Purpose To demonstrate feasibility of developing a noninvasive extracellular pH (pHe) mapping method on a clinical MRI scanner for molecular imaging of liver cancer. Methods In vivo pHe mapping has been demonstrated on preclinical scanners (e.g., 9.4T, 11.7T) with Biosensor Imaging of Redundant Deviation in Shifts (BIRDS), where the pHe readout by 3D chemical shift imaging (CSI) depends on hyperfine shifts emanating from paramagnetic macrocyclic chelates like TmDOTP5− which upon extravasation from blood resides in the extracellular space. We implemented BIRDS‐based pHe mapping on a clinical 3T Siemens scanner, where typically diamagnetic 1H signals are detected using millisecond‐long radiofrequency (RF) pulses, and 1H shifts span over ±10 ppm with long transverse (T2, 102 ms) and longitudinal (T1, 103 ms) relaxation times. We modified this 3D‐CSI method for ultra‐fast acquisition with microsecond‐long RF pulses, because even at 3T the paramagnetic 1H shifts of TmDOTP5− have millisecond‐long T2 and T1 and ultra‐wide chemical shifts (±200 ppm) as previously observed in ultra‐high magnetic fields. Results We validated BIRDS‐based pH in vitro with a pH electrode. We measured pHe in a rabbit model for liver cancer using VX2 tumors, which are highly vascularized and hyperglycolytic. Compared to intratumoral pHe (6.8 ± 0.1; P < 10−9) and tumor's edge pHe (6.9 ± 0.1; P < 10−7), liver parenchyma pHe was significantly higher (7.2 ± 0.1). Tumor localization was confirmed with histopathological markers of necrosis (hematoxylin and eosin), glucose uptake (glucose transporter 1), and tissue acidosis (lysosome‐associated membrane protein 2). Conclusion This work demonstrates feasibility and potential clinical translatability of high‐resolution pHe mapping to monitor tumor aggressiveness and therapeutic outcome, all to improve personalized cancer treatment planning.